JP2009535644A - バイオマーカーを使用して疾患状況を同定するための方法および装置 - Google Patents
バイオマーカーを使用して疾患状況を同定するための方法および装置 Download PDFInfo
- Publication number
- JP2009535644A JP2009535644A JP2009509959A JP2009509959A JP2009535644A JP 2009535644 A JP2009535644 A JP 2009535644A JP 2009509959 A JP2009509959 A JP 2009509959A JP 2009509959 A JP2009509959 A JP 2009509959A JP 2009535644 A JP2009535644 A JP 2009535644A
- Authority
- JP
- Japan
- Prior art keywords
- biomarker
- symptom
- data
- biomarker data
- negative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000090 biomarker Substances 0.000 title claims abstract description 434
- 201000010099 disease Diseases 0.000 title claims abstract description 189
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 189
- 238000000034 method Methods 0.000 title claims abstract description 69
- 208000024891 symptom Diseases 0.000 claims abstract description 113
- 238000013179 statistical model Methods 0.000 claims abstract description 21
- 238000004458 analytical method Methods 0.000 claims description 128
- 238000009826 distribution Methods 0.000 claims description 37
- 230000001186 cumulative effect Effects 0.000 claims description 27
- 238000004590 computer program Methods 0.000 claims description 15
- 230000001419 dependent effect Effects 0.000 claims description 8
- 239000002131 composite material Substances 0.000 abstract description 20
- 230000000295 complement effect Effects 0.000 description 22
- 230000008569 process Effects 0.000 description 18
- 206010006187 Breast cancer Diseases 0.000 description 16
- 208000026310 Breast neoplasm Diseases 0.000 description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 14
- 102000004890 Interleukin-8 Human genes 0.000 description 13
- 108090001007 Interleukin-8 Proteins 0.000 description 13
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 13
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 13
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 13
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 13
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 13
- 238000003745 diagnosis Methods 0.000 description 13
- 229940096397 interleukin-8 Drugs 0.000 description 13
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 13
- 238000012545 processing Methods 0.000 description 13
- 108010053455 riboflavin-binding protein Proteins 0.000 description 13
- 239000003550 marker Substances 0.000 description 12
- 102000004889 Interleukin-6 Human genes 0.000 description 11
- 108090001005 Interleukin-6 Proteins 0.000 description 11
- 229940100601 interleukin-6 Drugs 0.000 description 11
- 239000000523 sample Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000012472 biological sample Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 5
- 230000000153 supplemental effect Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- -1 elements Substances 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009247 menarche Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Biophysics (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Genetics & Genomics (AREA)
- Primary Health Care (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioethics (AREA)
- Artificial Intelligence (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/381,104 US20070255113A1 (en) | 2006-05-01 | 2006-05-01 | Methods and apparatus for identifying disease status using biomarkers |
| PCT/US2007/067418 WO2007130831A2 (en) | 2006-05-01 | 2007-04-25 | Methods and apparatus for identifying disease status using biomarkers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009535644A true JP2009535644A (ja) | 2009-10-01 |
| JP2009535644A5 JP2009535644A5 (enExample) | 2011-06-30 |
Family
ID=38648787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009509959A Withdrawn JP2009535644A (ja) | 2006-05-01 | 2007-04-25 | バイオマーカーを使用して疾患状況を同定するための方法および装置 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20070255113A1 (enExample) |
| EP (2) | EP2016405B1 (enExample) |
| JP (1) | JP2009535644A (enExample) |
| KR (1) | KR20090024686A (enExample) |
| CN (1) | CN101479599A (enExample) |
| AU (1) | AU2007248299A1 (enExample) |
| BR (1) | BRPI0711148A2 (enExample) |
| CA (1) | CA2650872C (enExample) |
| IL (1) | IL195054A0 (enExample) |
| MX (1) | MX2008013978A (enExample) |
| RU (1) | RU2008147223A (enExample) |
| WO (1) | WO2007130831A2 (enExample) |
| ZA (1) | ZA200809968B (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014121323A (ja) * | 2012-12-21 | 2014-07-03 | Stembios Technologies Inc | 幹細胞による行為効果を評価する方法 |
| JP2017516085A (ja) * | 2014-04-08 | 2017-06-15 | メタボルン インコーポレーティッド | 疾患診断および健康評価のための個々の対象の低分子生化学プロファイリングの方法 |
| US10143710B2 (en) | 2010-08-04 | 2018-12-04 | StemBios Technologies, Inc. | Somatic stem cells |
| US11492592B2 (en) | 2012-12-06 | 2022-11-08 | StemBios Technologies, Inc. | Lgr5+ somatic stem cells |
| JP2023086821A (ja) * | 2016-01-22 | 2023-06-22 | オートレイシーズ，インク． | 疾患診断を改善するシステム及び方法 |
| JP2023156388A (ja) * | 2013-03-14 | 2023-10-24 | オートレイシーズ・インコーポレイテッド | 測定分析物を使用する、疾患診断を改善するための方法 |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158374B1 (en) | 2006-09-05 | 2012-04-17 | Ridge Diagnostics, Inc. | Quantitative diagnostic methods using multiple parameters |
| US20090047694A1 (en) * | 2007-08-17 | 2009-02-19 | Shuber Anthony P | Clinical Intervention Directed Diagnostic Methods |
| US8431367B2 (en) | 2007-09-14 | 2013-04-30 | Predictive Biosciences Corporation | Detection of nucleic acids and proteins |
| US20090075266A1 (en) * | 2007-09-14 | 2009-03-19 | Predictive Biosciences Corporation | Multiple analyte diagnostic readout |
| US20100267041A1 (en) * | 2007-09-14 | 2010-10-21 | Predictive Biosciences, Inc. | Serial analysis of biomarkers for disease diagnosis |
| US7955822B2 (en) * | 2007-09-14 | 2011-06-07 | Predictive Biosciences Corp. | Detection of nucleic acids and proteins |
| EP2329260A4 (en) * | 2008-03-04 | 2011-08-03 | Ridge Diagnostics Inc | DIAGNOSIS AND MONITORING OF DEPRESSIVE DISORDERS BASED ON A PLURALITY OF BIOMARKER PANELS |
| JP5658571B2 (ja) * | 2008-03-12 | 2015-01-28 | リッジ ダイアグノスティックス，インコーポレイテッド | うつ障害をモニタリングするための炎症バイオマーカー |
| US20140342381A1 (en) * | 2008-08-11 | 2014-11-20 | Banyan Biomarkers, Inc. | Devices and methods for biomarker detection process and assay of neurological condition |
| JP5781436B2 (ja) | 2008-08-11 | 2015-09-24 | バンヤン・バイオマーカーズ・インコーポレーテッド | 神経学的状態のバイオマーカー検出方法およびアッセイ |
| WO2010059709A2 (en) | 2008-11-18 | 2010-05-27 | Ridge Diagnostics, Inc. | Metabolic syndrome and hpa axis biomarkers for major depressive disorder |
| WO2011025953A1 (en) * | 2009-08-28 | 2011-03-03 | Lexicor Medical Technology, Llc | Systems and methods to identify a subgroup of adhd at higher risk for complicating conditions |
| US20150127378A1 (en) * | 2012-02-11 | 2015-05-07 | Yougene Corp. | Systems for storing, processing and utilizing proprietary genetic information |
| JP6075973B2 (ja) * | 2012-06-04 | 2017-02-08 | 富士通株式会社 | 健康状態判定装置およびその作動方法 |
| EP2684513A1 (en) * | 2012-07-13 | 2014-01-15 | Universite D'angers | Method for providing reliable non-invasive diagnostic tests |
| US20140275294A1 (en) * | 2013-03-15 | 2014-09-18 | Banyan Biomarkers, Inc. | Devices and methods for biomarker detection process and assay of liver injury |
| CN103279655A (zh) * | 2013-05-20 | 2013-09-04 | 浙江大学 | 一种恶性肿瘤放化疗规范符合度的评估方法 |
| AU2014268417A1 (en) | 2013-05-23 | 2015-11-26 | Iphenotype Llc | Methods and systems for assisting persons, product providers and/or service providers |
| WO2014201516A2 (en) | 2013-06-20 | 2014-12-24 | Immunexpress Pty Ltd | Biomarker identification |
| JP6703479B2 (ja) | 2013-12-16 | 2020-06-03 | フィリップ モリス プロダクツ エス アー | 個人の喫煙ステータスを予測するためのシステムおよび方法 |
| EP3103046B1 (en) | 2014-02-06 | 2020-03-25 | Immunexpress Pty Ltd | Biomarker signature method, and apparatus and kits therefor |
| US9176113B1 (en) | 2014-04-11 | 2015-11-03 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
| US20150294081A1 (en) | 2014-04-11 | 2015-10-15 | Synapdx Corporation | Methods and systems for determining autism spectrum disorder risk |
| US10525020B2 (en) | 2015-02-11 | 2020-01-07 | Laboratory Corporation Of America Holdings | Metabolic markers of attention deficit hyperactivity disorder |
| AU2016267392B2 (en) * | 2015-05-28 | 2021-12-09 | Immunexpress Pty Ltd | Validating biomarker measurement |
| US11594311B1 (en) | 2016-03-31 | 2023-02-28 | OM1, Inc. | Health care information system providing standardized outcome scores across patients |
| US11957897B2 (en) | 2016-04-22 | 2024-04-16 | Newton Howard | Biological co-processor (BCP) |
| CN110366558A (zh) | 2016-10-28 | 2019-10-22 | 班扬生物标记公司 | 针对泛素c末端水解酶l1(uch-l1)和胶质纤维酸性蛋白(gfap)的抗体及相关方法 |
| WO2019183052A1 (en) * | 2018-03-19 | 2019-09-26 | Sri International | Methods and systems for biomarker analysis |
| US20190302119A1 (en) * | 2018-03-27 | 2019-10-03 | Lawrence Abraham | Cancer Diagnostic Metastasis Panel |
| US11967428B1 (en) * | 2018-04-17 | 2024-04-23 | OM1, Inc. | Applying predictive models to data representing a history of events |
| CA3003032A1 (en) * | 2018-04-27 | 2019-10-27 | Nanostics Inc. | Methods of diagnosing disease using microflow cytometry |
| LU100835B1 (en) * | 2018-06-13 | 2019-12-13 | Univ Muenster Westfaelische Wilhelms | Novel biomarkers for recurrent tonsillitis |
| US11862346B1 (en) | 2018-12-22 | 2024-01-02 | OM1, Inc. | Identification of patient sub-cohorts and corresponding quantitative definitions of subtypes as a classification system for medical conditions |
| EP3935581A4 (en) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING |
| US20200395097A1 (en) * | 2019-05-30 | 2020-12-17 | Tempus Labs, Inc. | Pan-cancer model to predict the pd-l1 status of a cancer cell sample using rna expression data and other patient data |
| TWI740647B (zh) * | 2020-09-15 | 2021-09-21 | 宏碁股份有限公司 | 疾病分類方法及疾病分類裝置 |
| US20220223231A1 (en) * | 2021-01-14 | 2022-07-14 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and Methods for Improved Prognostics in Medical Imaging |
| KR102671925B1 (ko) * | 2022-03-03 | 2024-06-03 | 인제대학교 산학협력단 | 파킨슨병 진단 방법 및 그 시스템 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197532B1 (en) * | 1998-01-22 | 2001-03-06 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Diagnosis and detection of breast cancer and other cancers |
| US6882990B1 (en) * | 1999-05-01 | 2005-04-19 | Biowulf Technologies, Llc | Methods of identifying biological patterns using multiple data sets |
| US20020115070A1 (en) * | 1999-03-15 | 2002-08-22 | Pablo Tamayo | Methods and apparatus for analyzing gene expression data |
| US6647341B1 (en) * | 1999-04-09 | 2003-11-11 | Whitehead Institute For Biomedical Research | Methods for classifying samples and ascertaining previously unknown classes |
| US6750013B2 (en) * | 1999-12-02 | 2004-06-15 | Protein Design Labs, Inc. | Methods for detection and diagnosing of breast cancer |
| AU2002339841A1 (en) * | 2001-07-13 | 2003-01-29 | Dana-Farber Cancer Institute, Inc. | Leukemogenic transcription factors |
| WO2003041562A2 (en) * | 2001-11-14 | 2003-05-22 | Whitehead Institute For Biomedical Research | Molecular cancer diagnosis using tumor gene expression signature |
| US6949342B2 (en) * | 2001-12-21 | 2005-09-27 | Whitehead Institute For Biomedical Research | Prostate cancer diagnosis and outcome prediction by expression analysis |
| CA2499636A1 (en) * | 2002-04-01 | 2003-10-16 | Phase-1 Molecular Toxicology, Inc. | Liver necrosis predictive genes |
| US20050176057A1 (en) * | 2003-09-26 | 2005-08-11 | Troy Bremer | Diagnostic markers of mood disorders and methods of use thereof |
-
2006
- 2006-05-01 US US11/381,104 patent/US20070255113A1/en not_active Abandoned
-
2007
- 2007-02-28 US US11/679,960 patent/US20070254369A1/en not_active Abandoned
- 2007-04-25 CA CA2650872A patent/CA2650872C/en active Active
- 2007-04-25 EP EP07761281.0A patent/EP2016405B1/en not_active Not-in-force
- 2007-04-25 CN CNA2007800237208A patent/CN101479599A/zh active Pending
- 2007-04-25 RU RU2008147223/14A patent/RU2008147223A/ru not_active Application Discontinuation
- 2007-04-25 EP EP17192958.1A patent/EP3318995A1/en not_active Withdrawn
- 2007-04-25 MX MX2008013978A patent/MX2008013978A/es not_active Application Discontinuation
- 2007-04-25 BR BRPI0711148-7A patent/BRPI0711148A2/pt not_active IP Right Cessation
- 2007-04-25 JP JP2009509959A patent/JP2009535644A/ja not_active Withdrawn
- 2007-04-25 KR KR1020087029423A patent/KR20090024686A/ko not_active Withdrawn
- 2007-04-25 AU AU2007248299A patent/AU2007248299A1/en not_active Abandoned
- 2007-04-25 WO PCT/US2007/067418 patent/WO2007130831A2/en not_active Ceased
-
2008
- 2008-11-02 IL IL195054A patent/IL195054A0/en unknown
- 2008-11-24 ZA ZA200809968A patent/ZA200809968B/xx unknown
-
2010
- 2010-12-07 US US12/962,162 patent/US20110077931A1/en not_active Abandoned
-
2012
- 2012-11-02 US US13/667,842 patent/US20130060549A1/en not_active Abandoned
-
2020
- 2020-01-28 US US16/775,233 patent/US20210041440A1/en not_active Abandoned
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10143710B2 (en) | 2010-08-04 | 2018-12-04 | StemBios Technologies, Inc. | Somatic stem cells |
| US11492592B2 (en) | 2012-12-06 | 2022-11-08 | StemBios Technologies, Inc. | Lgr5+ somatic stem cells |
| JP2014121323A (ja) * | 2012-12-21 | 2014-07-03 | Stembios Technologies Inc | 幹細胞による行為効果を評価する方法 |
| JP2023156388A (ja) * | 2013-03-14 | 2023-10-24 | オートレイシーズ・インコーポレイテッド | 測定分析物を使用する、疾患診断を改善するための方法 |
| JP7603115B2 (ja) | 2013-03-14 | 2024-12-19 | オートレイシーズ・インコーポレイテッド | 測定分析物を使用する、疾患診断を改善するための方法 |
| JP2017516085A (ja) * | 2014-04-08 | 2017-06-15 | メタボルン インコーポレーティッド | 疾患診断および健康評価のための個々の対象の低分子生化学プロファイリングの方法 |
| JP2023086821A (ja) * | 2016-01-22 | 2023-06-22 | オートレイシーズ，インク． | 疾患診断を改善するシステム及び方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL195054A0 (en) | 2009-08-03 |
| AU2007248299A1 (en) | 2007-11-15 |
| US20210041440A1 (en) | 2021-02-11 |
| KR20090024686A (ko) | 2009-03-09 |
| EP2016405B1 (en) | 2017-09-27 |
| US20070254369A1 (en) | 2007-11-01 |
| EP2016405A4 (en) | 2012-10-03 |
| CA2650872C (en) | 2018-04-24 |
| EP2016405A2 (en) | 2009-01-21 |
| CN101479599A (zh) | 2009-07-08 |
| WO2007130831A3 (en) | 2008-10-30 |
| MX2008013978A (es) | 2009-02-19 |
| US20110077931A1 (en) | 2011-03-31 |
| CA2650872A1 (en) | 2007-11-15 |
| EP3318995A1 (en) | 2018-05-09 |
| ZA200809968B (en) | 2009-08-26 |
| RU2008147223A (ru) | 2010-06-10 |
| US20130060549A1 (en) | 2013-03-07 |
| WO2007130831A2 (en) | 2007-11-15 |
| BRPI0711148A2 (pt) | 2011-08-23 |
| US20070255113A1 (en) | 2007-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210041440A1 (en) | Methods and apparatus for identifying disease status using biomarkers | |
| US11651189B2 (en) | Methods and systems of evaluating a risk of a gastrointestinal cancer | |
| CN105229471B (zh) | 用于基于生物化学标记分析确定先兆子痫风险的系统和方法 | |
| Lacher et al. | Biological variation of laboratory analytes based on the 1999-2002 National Health and Nutrition Examination Survey | |
| US20130210667A1 (en) | Biomarkers for Predicting Kidney and Glomerular Pathologies | |
| US20190018930A1 (en) | Method for building a database | |
| CN116779077A (zh) | 基于体检标志物构建生物学年龄及衰老评价的方法及系统 | |
| Oosterhuis et al. | The science of systematic reviewing studies of diagnostic tests | |
| Marakala | Head and neck cancer biomarkers: Systematic review and meta-analysis | |
| CN115698712A (zh) | 预测类风湿关节炎的疾病进展的方法 | |
| Yucel et al. | The effect of lactate/albumin ratio on mortality in patients with sepsis | |
| CN119694566A (zh) | 基于Ai的脓毒血症的化学指标检测系统 | |
| CN121002198A (zh) | 用于鉴别一种或多种预测性生物标志物的人工智能 | |
| CN118016288A (zh) | 老年原发性结直肠淋巴瘤预后动态风险预测方法和系统 | |
| Kraut et al. | Re-evaluation of total CO2 concentration in apparently healthy younger adults | |
| Vrbanic et al. | Intracranial haemorrhage and falls: cause or effect? | |
| WO2022210606A1 (ja) | 認知症の将来の発症リスクの評価方法 | |
| Qi et al. | Development of a clinical prediction model for intra-abdominal infection in severe acute pancreatitis using logistic regression and nomogram | |
| Suzuki et al. | C-reactive protein and lactate dehydrogenase are useful biomarkers for predicting the requirement for oxygen therapy in outpatients with coronavirus disease 2019 | |
| WO2009108196A1 (en) | Methods and apparatus for identifying disease status using biomarkers | |
| TW202418295A (zh) | 癌症進展判別方法及其系統 | |
| Liu et al. | Association of longitudinal body mass index trajectories with phenotypic age acceleration: a cross-sectional study based on growth mixture modeling | |
| Cullen | The application of predictive statistical modelling in the investigation of suspected classical Myeloproliferative Neoplasms | |
| Pestana | Study of biomarkers in Multiple Myeloma: a statistical approach for longitudinal assessment of extracellular vesicles and its prognostic value | |
| CN114628026A (zh) | 诊断hcm的装置、预测hcm患者预后的装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100420 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100420 |
|
| A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A073 Effective date: 20110902 |
|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20110906 |